July 28, 2021

Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates

July 20, 2021

Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids

July 14, 2021

Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021

June 1, 2021

Myovant Sciences to Present at Upcoming Investor Conferences

May 26, 2021

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

May 21, 2021

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

May 11, 2021

Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021

May 4, 2021

Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021

April 12, 2021

Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet

April 5, 2021

Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer